{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:12:18Z","timestamp":1782987138614,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00246-024-03513-w","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T08:01:36Z","timestamp":1715328096000},"page":"902-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"46","author":[{"given":"Madeline","family":"Grossman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Zachary","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"issue":"9","key":"3513_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","volume":"38","author":"G Hansmann","year":"2019","unstructured":"Hansmann G, Koestenberger M, Alastalo TP et al (2019) 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 38(9):879\u2013901. https:\/\/doi.org\/10.1016\/j.healun.2019.06.022","journal-title":"J Heart Lung Transplant"},{"issue":"3 Suppl 1","key":"3513_CR2","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1097\/PCC.0000000000000622","volume":"17","author":"JS Kim","year":"2016","unstructured":"Kim JS, McSweeney J, Lee J, Ivy D (2016) Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: pharmacotherapies in cardiac critical care pulmonary hypertension. Pediatr Crit Care Med 17(3 Suppl 1):S89\u2013S100. https:\/\/doi.org\/10.1097\/PCC.0000000000000622","journal-title":"Pediatr Crit Care Med"},{"issue":"4","key":"3513_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.21037\/cdt-20-912","volume":"11","author":"M Gorenflo","year":"2021","unstructured":"Gorenflo M, Ziesenitz VC (2021) Treatment of pulmonary arterial hypertension in children. Cardiovasc Diagn Ther 11(4):1144\u20131159. https:\/\/doi.org\/10.21037\/cdt-20-912","journal-title":"Cardiovasc Diagn Ther"},{"key":"3513_CR4","unstructured":"Remodulin\u00ae (treprostinil) Injection, for subcutaneous or intravenous use [package insert]. Research Triangle Park: Unite Therapeutics Corp.; 2002"},{"key":"3513_CR5","unstructured":"Veletri (epoprostenol) for Injection [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 1995"},{"key":"3513_CR6","unstructured":"Flolan\u00ae (epoprostenol) for Injection [package insert]. Research Triangle Park: GlaxoSmithKline; 2008"},{"key":"3513_CR7","unstructured":"Ventavis\u00ae (iloprost) inhalation solution, for oral inhalation use [package insert]. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; 2004"},{"key":"3513_CR8","unstructured":"Orenitram\u00ae (treprostinil) extended-release tablets, for oral use [package insert]. Research Triangle Park: Unite Therapeutics Corp.; 2002"},{"key":"3513_CR9","unstructured":"Uptravi\u00ae (selexipag) [package insert]. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; 2022"},{"issue":"1","key":"3513_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/FJC.0000000000000820","volume":"76","author":"A Gavotto","year":"2020","unstructured":"Gavotto A, Thomas F, Werner O et al (2020) Use of treprostinil in pediatric pulmonary hypertension: case reports and review of the literature. J Cardiovasc Pharmacol 76(1):23\u201331. https:\/\/doi.org\/10.1097\/FJC.0000000000000820","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"3513_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.11-2212","volume":"142","author":"VF Tapson","year":"2012","unstructured":"Tapson VF, Torres F, Kermeen F et al (2012) Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 142(6):1383\u20131390. https:\/\/doi.org\/10.1378\/chest.11-2212","journal-title":"Chest"},{"issue":"26","key":"3513_CR12","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, Ghofrani H-A, Hoeper MM, Lang IN, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, GRIPHON Investigators (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522\u20132533. https:\/\/doi.org\/10.1056\/NEJMoa1503184","journal-title":"N Engl J Med"},{"issue":"2","key":"3513_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12224","volume":"13","author":"J McSweeney","year":"2023","unstructured":"McSweeney J, Colglazier E, Becerra J et al (2023) Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients. Pulm Circ 13(2):e12224. https:\/\/doi.org\/10.1002\/pul2.12224","journal-title":"Pulm Circ"},{"issue":"7","key":"3513_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.healun.2020.03.029","volume":"39","author":"G Hansmann","year":"2020","unstructured":"Hansmann G, Meinel K, Bukova M, Chouvarine P, W\u00e5hlander H, Koestenberger M, European Pediatric Pulmonary Vascular Disease Network (EPPVDN) (2020) Selexipag for the treatment of children with pulmonary arterial hypertension: first multicenter experience in drug safety and efficacy. J Heart Lung Transplant 39(7):695\u2013706. https:\/\/doi.org\/10.1016\/j.healun.2020.03.029","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"3513_CR15","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00246-017-1677-7","volume":"38","author":"R Gallotti","year":"2017","unstructured":"Gallotti R, Drogalis-Kim DE, Satou G, Alejos J (2017) Single-center experience using selexipag in a pediatric population. Pediatr Cardiol 38(7):1405\u20131409. https:\/\/doi.org\/10.1007\/s00246-017-1677-7","journal-title":"Pediatr Cardiol"},{"issue":"9","key":"3513_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1017\/S1047951121000937","volume":"31","author":"A Lafuente-Romero","year":"2021","unstructured":"Lafuente-Romero A, Rodriguez OA (2021) Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients. Cardiol Young 31(9):1513\u20131515. https:\/\/doi.org\/10.1017\/S1047951121000937","journal-title":"Cardiol Young"},{"issue":"11","key":"3513_CR17","doi-asserted-by":"publisher","first-page":"1055158","DOI":"10.3389\/fped.2023.1055158","volume":"28","author":"D Youssef","year":"2023","unstructured":"Youssef D, Richards S, Lague S et al (2023) A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients. Front Pediatr 28(11):1055158. https:\/\/doi.org\/10.3389\/fped.2023.1055158","journal-title":"Front Pediatr"},{"issue":"4","key":"3513_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12159","volume":"12","author":"E Colglazier","year":"2022","unstructured":"Colglazier E, Stevens L, Parker C et al (2022) Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension. Pulm Circ 12(4):e12159. https:\/\/doi.org\/10.1002\/pul2.12159","journal-title":"Pulm Circ"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-024-03513-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-024-03513-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-024-03513-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:31:39Z","timestamp":1741793499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-024-03513-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3513"],"URL":"https:\/\/doi.org\/10.1007\/s00246-024-03513-w","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was waived by the local Ethics Committee of Children\u2019s Hospital of Philadelphia in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}